Header Logo

Connection

Alan Go to Atrial Fibrillation

Back to Details
This is a "connection" page, showing publications Alan Go has written about Atrial Fibrillation.
Alan Go
Connection Strength
18.529
Atrial Fibrillation
  1. Incident Atrial Fibrillation and Risk of Dementia in a Diverse, Community-Based Population. J Am Heart Assoc. 2023 03 21; 12(6):e028290.
    View in: PubMed
    Score: 0.712
  2. Research Opportunities in Stroke Prevention for Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop. Stroke. 2023 Mar; 54(3):e75-e85.
    View in: PubMed
    Score: 0.711
  3. Advancing Research on the Complex Interrelations Between Atrial Fibrillation and Heart Failure: A Report From a US National Heart, Lung, and Blood Institute Virtual Workshop. Circulation. 2020 06 09; 141(23):1915-1926.
    View in: PubMed
    Score: 0.588
  4. Comparison of Long-Term Adverse Outcomes in Patients With Atrial Fibrillation Having Ablation Versus Antiarrhythmic Medications. Am J Cardiol. 2020 02 15; 125(4):553-561.
    View in: PubMed
    Score: 0.566
  5. Thromboprophylaxis for Patients with High-risk Atrial Fibrillation and Flutter Discharged from the Emergency Department. West J Emerg Med. 2018 Mar; 19(2):346-360.
    View in: PubMed
    Score: 0.501
  6. Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice: A Retrospective Cohort Study. Ann Intern Med. 2017 Dec 19; 167(12):845-854.
    View in: PubMed
    Score: 0.493
  7. Digoxin and risk of death in adults with atrial fibrillation: the ATRIA-CVRN study. Circ Arrhythm Electrophysiol. 2015 Feb; 8(1):49-58.
    View in: PubMed
    Score: 0.401
  8. Incident atrial fibrillation and risk of death in adults with chronic kidney disease. J Am Heart Assoc. 2014 Oct 20; 3(5):e001303.
    View in: PubMed
    Score: 0.398
  9. Intersection of cardiovascular disease and kidney disease: atrial fibrillation. Curr Opin Nephrol Hypertens. 2014 May; 23(3):275-82.
    View in: PubMed
    Score: 0.385
  10. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc. 2013 Jun 21; 2(3):e000250.
    View in: PubMed
    Score: 0.363
  11. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation. 2013 Feb 05; 127(5):569-74.
    View in: PubMed
    Score: 0.351
  12. Detection of paroxysmal atrial fibrillation by 30-day event monitoring in cryptogenic ischemic stroke: the Stroke and Monitoring for PAF in Real Time (SMART) Registry. Stroke. 2012 Oct; 43(10):2788-90.
    View in: PubMed
    Score: 0.342
  13. CHA2DS2-VASc risk scheme: not ready for clinical use. Chest. 2010 Oct; 138(4):1020; author reply 1020-1.
    View in: PubMed
    Score: 0.301
  14. The international normalized ratio range of 2.0 to 3.0 remains appropriate for atrial fibrillation. Arch Intern Med. 2009 Nov 23; 169(21):2032; author reply 2033.
    View in: PubMed
    Score: 0.283
  15. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009 Sep 01; 151(5):297-305.
    View in: PubMed
    Score: 0.279
  16. Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study. Circ Cardiovasc Qual Outcomes. 2009 Jul; 2(4):297-304.
    View in: PubMed
    Score: 0.275
  17. The ACTIVE pursuit of stroke prevention in patients with atrial fibrillation. N Engl J Med. 2009 May 14; 360(20):2127-9.
    View in: PubMed
    Score: 0.273
  18. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation. 2009 Mar 17; 119(10):1363-9.
    View in: PubMed
    Score: 0.269
  19. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke. 2008 Jun; 39(6):1901-10.
    View in: PubMed
    Score: 0.254
  20. Stroke prevention in atrial fibrillation: another step sideways. Lancet. 2008 Jan 26; 371(9609):278-80.
    View in: PubMed
    Score: 0.250
  21. Effect of race/ethnicity on the efficacy of warfarin: potential implications for prevention of stroke in patients with atrial fibrillation. CNS Drugs. 2008; 22(10):815-25.
    View in: PubMed
    Score: 0.249
  22. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation. 2005 Sep 20; 112(12):1687-91.
    View in: PubMed
    Score: 0.212
  23. Antithrombotic therapy for stroke prevention in atrial fibrillation. Prog Cardiovasc Dis. 2005 Sep-Oct; 48(2):108-24.
    View in: PubMed
    Score: 0.211
  24. Association of Rate-Control and Antiarrhythmic Medication Use and Risk of Ischemic Stroke and Death in Patients on Dialysis With Atrial Fibrillation. J Am Heart Assoc. 2025 Jun 17; 14(12):e038511.
    View in: PubMed
    Score: 0.208
  25. Anticoagulants for stroke prevention in atrial fibrillation: what is the right rate and where do we go from here? Nat Clin Pract Cardiovasc Med. 2005 May; 2(5):226-7.
    View in: PubMed
    Score: 0.207
  26. The epidemiology of atrial fibrillation in elderly persons: the tip of the iceberg. Am J Geriatr Cardiol. 2005 Mar-Apr; 14(2):56-61.
    View in: PubMed
    Score: 0.204
  27. Decision Support Intervention and Anticoagulation for Emergency Department Atrial Fibrillation: The O'CAF? Stepped-Wedge Cluster Randomized Clinical Trial. JAMA Netw Open. 2024 Nov 04; 7(11):e2443097.
    View in: PubMed
    Score: 0.200
  28. Effect of Screening for Undiagnosed?Atrial Fibrillation on?Stroke?Prevention. J Am Coll Cardiol. 2024 Nov 19; 84(21):2073-2084.
    View in: PubMed
    Score: 0.197
  29. Economic implications of transesophageal echocardiography-guided cardioversion of atrial fibrillation. J Am Coll Cardiol. 2004 Apr 07; 43(7):1225-7.
    View in: PubMed
    Score: 0.192
  30. Efficacy of anticoagulation for stroke prevention and risk stratification in atrial fibrillation: translating trials into clinical practice. Am J Manag Care. 2004 Apr; 10(3 Suppl):S58-65.
    View in: PubMed
    Score: 0.192
  31. Racial variation in the prevalence of atrial fibrillation among patients with heart failure: the Epidemiology, Practice, Outcomes, and Costs of Heart Failure (EPOCH) study. J Am Coll Cardiol. 2004 Feb 04; 43(3):429-35.
    View in: PubMed
    Score: 0.190
  32. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA. 2003 Nov 26; 290(20):2685-92.
    View in: PubMed
    Score: 0.187
  33. Gaps in guideline-recommended anticoagulation in patients with atrial fibrillation and elevated thromboembolic risk within an integrated healthcare delivery system. BMC Cardiovasc Disord. 2023 11 21; 23(1):578.
    View in: PubMed
    Score: 0.187
  34. Clinical decision support to Optimize Care of patients with Atrial Fibrillation or flutter in the Emergency department: protocol of a stepped-wedge cluster randomized pragmatic trial (O'CAF? trial). Trials. 2023 Mar 31; 24(1):246.
    View in: PubMed
    Score: 0.179
  35. Factor V Leiden and risk of ischemic stroke in nonvalvular atrial fibrillation: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. J Thromb Thrombolysis. 2003 Feb; 15(1):41-6.
    View in: PubMed
    Score: 0.177
  36. Transforming Atrial Fibrillation Research to Integrate Social Determinants of Health: A National Heart, Lung, and Blood Institute Workshop Report. JAMA Cardiol. 2023 Feb 01; 8(2):182-191.
    View in: PubMed
    Score: 0.177
  37. ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals (GUARD-AF): Rationale and design of the GUARD-AF randomized trial of screening for atrial fibrillation with a 14-day patch-based continuous ECG monitor. Am Heart J. 2022 07; 249:76-85.
    View in: PubMed
    Score: 0.168
  38. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001 May 09; 285(18):2370-5.
    View in: PubMed
    Score: 0.157
  39. Antithrombotic therapy in atrial fibrillation. Clin Geriatr Med. 2001 Feb; 17(1):131-47.
    View in: PubMed
    Score: 0.154
  40. Change in Cardiac Biomarkers and Risk of Incident Heart Failure and Atrial Fibrillation in CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis. 2021 06; 77(6):907-919.
    View in: PubMed
    Score: 0.152
  41. Shared decision-making in atrial fibrillation: patient-reported involvement in treatment decisions. Eur Heart J Qual Care Clin Outcomes. 2020 10 01; 6(4):263-272.
    View in: PubMed
    Score: 0.150
  42. Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Circulation. 2000 Jul 04; 102(1):11-3.
    View in: PubMed
    Score: 0.148
  43. Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). Am Heart J. 2020 08; 226:85-93.
    View in: PubMed
    Score: 0.146
  44. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med. 1999 Dec 21; 131(12):927-34.
    View in: PubMed
    Score: 0.142
  45. Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation. Circ Arrhythm Electrophysiol. 2019 12; 12(12):e007612.
    View in: PubMed
    Score: 0.142
  46. Research Needs and Priorities for Catheter Ablation of Atrial Fibrillation: A Report From a National Heart, Lung, and Blood Institute Virtual Workshop. Circulation. 2020 02 11; 141(6):482-492.
    View in: PubMed
    Score: 0.142
  47. Net Clinical Benefit of Oral Anticoagulation Among Older Adults With Atrial Fibrillation. Circ Cardiovasc Qual Outcomes. 2019 11; 12(11):e006212.
    View in: PubMed
    Score: 0.141
  48. Cardiac Biomarkers and Risk of Atrial Fibrillation in Chronic Kidney Disease: The CRIC Study. J Am Heart Assoc. 2019 08 06; 8(15):e012200.
    View in: PubMed
    Score: 0.139
  49. Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. Am Heart J. 2019 07; 213:81-90.
    View in: PubMed
    Score: 0.136
  50. Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. J Thromb Thrombolysis. 2018 Nov; 46(4):435-439.
    View in: PubMed
    Score: 0.132
  51. Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation. Heart. 2018 11; 104(22):1850-1858.
    View in: PubMed
    Score: 0.128
  52. Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines: Findings From ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation). Circ Arrhythm Electrophysiol. 2017 Nov; 10(11).
    View in: PubMed
    Score: 0.123
  53. Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes: ORBIT-AF Registry. J Am Coll Cardiol. 2017 Sep 12; 70(11):1325-1335.
    View in: PubMed
    Score: 0.122
  54. Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry. Eur Heart J Qual Care Clin Outcomes. 2017 07 01; 3(3):192-197.
    View in: PubMed
    Score: 0.120
  55. Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation. Clin Cardiol. 2017 Sep; 40(9):746-751.
    View in: PubMed
    Score: 0.119
  56. Health Literacy and Awareness of Atrial Fibrillation. J Am Heart Assoc. 2017 Apr 11; 6(4).
    View in: PubMed
    Score: 0.118
  57. Use of Oral Anticoagulant Therapy in Older Adults with Atrial Fibrillation After Acute Ischemic Stroke. J Am Geriatr Soc. 2017 Feb; 65(2):241-248.
    View in: PubMed
    Score: 0.116
  58. Influence of Competing Risks on Estimating the Expected Benefit of Warfarin in Individuals with Atrial Fibrillation Not Currently Taking Anticoagulants: The Anticoagulation and Risk Factors in Atrial Fibrillation Study. J Am Geriatr Soc. 2017 01; 65(1):35-41.
    View in: PubMed
    Score: 0.115
  59. Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. Circulation. 2016 10 11; 134(15):1122-1124.
    View in: PubMed
    Score: 0.114
  60. Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study. JAMA Cardiol. 2016 Aug 01; 1(5):548-56.
    View in: PubMed
    Score: 0.113
  61. Stability of High-Quality Warfarin Anticoagulation in a Community-Based Atrial Fibrillation Cohort: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. J Am Heart Assoc. 2016 07 22; 5(7).
    View in: PubMed
    Score: 0.112
  62. How Well Do Stroke Risk Scores Predict Hemorrhage in Patients With Atrial Fibrillation? Am J Cardiol. 2016 09 01; 118(5):697-9.
    View in: PubMed
    Score: 0.112
  63. Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL. Circ Arrhythm Electrophysiol. 2016 06; 9(6).
    View in: PubMed
    Score: 0.111
  64. Atrial Fibrillation and Risk of ESRD in Adults with CKD. Clin J Am Soc Nephrol. 2016 07 07; 11(7):1189-96.
    View in: PubMed
    Score: 0.110
  65. Interleukin-6 Is a Risk Factor for Atrial Fibrillation in Chronic Kidney Disease: Findings from the CRIC Study. PLoS One. 2016; 11(2):e0148189.
    View in: PubMed
    Score: 0.109
  66. Effect of Diabetes and Glycemic Control on Ischemic Stroke Risk in AF Patients: ATRIA Study. J Am Coll Cardiol. 2016 Jan 26; 67(3):239-47.
    View in: PubMed
    Score: 0.109
  67. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. Am J Med. 2016 06; 129(6):592-599.e1.
    View in: PubMed
    Score: 0.109
  68. Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBIT-AF Registry. Clin Cardiol. 2016 Feb; 39(2):119-25.
    View in: PubMed
    Score: 0.108
  69. Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry. Am Heart J. 2016 Apr; 174:29-36.
    View in: PubMed
    Score: 0.108
  70. Anticoagulation in atrial fibrillation: impact of mental illness. Am J Manag Care. 2015 Nov 01; 21(11):e609-17.
    View in: PubMed
    Score: 0.107
  71. Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort. J Am Coll Cardiol. 2015 Jun 30; 65(25):2691-8.
    View in: PubMed
    Score: 0.104
  72. Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circ Cardiovasc Qual Outcomes. 2015 Jul; 8(4):393-402.
    View in: PubMed
    Score: 0.104
  73. Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. Am Heart J. 2015 Jul; 170(1):141-8, 148.e1.
    View in: PubMed
    Score: 0.103
  74. Comparison of frequency and outcome of major gastrointestinal hemorrhage in patients with atrial fibrillation on versus not receiving warfarin therapy (from the ATRIA and ATRIA-CVRN cohorts). Am J Cardiol. 2015 Jan 01; 115(1):40-6.
    View in: PubMed
    Score: 0.099
  75. Effect of selective serotonin reuptake inhibitors on bleeding risk in patients with atrial fibrillation taking warfarin. Am J Cardiol. 2014 Aug 15; 114(4):583-6.
    View in: PubMed
    Score: 0.097
  76. Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry. Am Heart J. 2014 Aug; 168(2):160-7.
    View in: PubMed
    Score: 0.096
  77. Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circulation. 2014 May 20; 129(20):2005-12.
    View in: PubMed
    Score: 0.096
  78. Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J. 2014 May; 167(5):735-42.e2.
    View in: PubMed
    Score: 0.095
  79. Long-term survival after ischemic stroke in patients with atrial fibrillation. Neurology. 2014 Mar 25; 82(12):1033-7.
    View in: PubMed
    Score: 0.095
  80. Lone atrial fibrillation: does it exist? J Am Coll Cardiol. 2014 May 06; 63(17):1715-23.
    View in: PubMed
    Score: 0.095
  81. Response to letter regarding article, "renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study cohorts". Circulation. 2013 Sep 10; 128(11):e172-3.
    View in: PubMed
    Score: 0.092
  82. Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. Circulation. 2013 Aug 13; 128(7):721-8.
    View in: PubMed
    Score: 0.091
  83. Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circ Cardiovasc Qual Outcomes. 2013 Jul; 6(4):461-9.
    View in: PubMed
    Score: 0.091
  84. Atrial fibrillation and outcomes in heart failure with preserved versus reduced left ventricular ejection fraction. J Am Heart Assoc. 2013 Feb 01; 2(1):e005694.
    View in: PubMed
    Score: 0.088
  85. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation. 2013 Jan 15; 127(2):224-32.
    View in: PubMed
    Score: 0.087
  86. Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. Stroke. 2012 Jul; 43(7):1795-9.
    View in: PubMed
    Score: 0.084
  87. Pharmacotherapy in Medicare beneficiaries with atrial fibrillation. Heart Rhythm. 2012 Sep; 9(9):1403-8.
    View in: PubMed
    Score: 0.084
  88. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb; 141(2 Suppl):e531S-e575S.
    View in: PubMed
    Score: 0.082
  89. Procedural complications, rehospitalizations, and repeat procedures after catheter ablation for atrial fibrillation. J Am Coll Cardiol. 2012 Jan 10; 59(2):143-9.
    View in: PubMed
    Score: 0.082
  90. Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. Am Heart J. 2011 Oct; 162(4):606-612.e1.
    View in: PubMed
    Score: 0.081
  91. Mental illness and warfarin use in atrial fibrillation. Am J Manag Care. 2011 Sep; 17(9):617-24.
    View in: PubMed
    Score: 0.080
  92. American Heart Association atrial fibrillation research summit: a conference report from the American Heart Association. Circulation. 2011 Jul 19; 124(3):363-72.
    View in: PubMed
    Score: 0.079
  93. Detection of atrial fibrillation after stroke and the risk of recurrent stroke. J Stroke Cerebrovasc Dis. 2012 Nov; 21(8):726-31.
    View in: PubMed
    Score: 0.078
  94. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011 Jan 04; 154(1):1-11.
    View in: PubMed
    Score: 0.076
  95. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010 Nov; 3(6):624-31.
    View in: PubMed
    Score: 0.075
  96. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J. 2010 Jun; 159(6):1102-7.
    View in: PubMed
    Score: 0.073
  97. Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation. 2009 Feb 03; 119(4):606-18.
    View in: PubMed
    Score: 0.067
  98. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):546S-592S.
    View in: PubMed
    Score: 0.064
  99. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2008 Feb 26; 51(8):810-5.
    View in: PubMed
    Score: 0.063
  100. ACC/AHA/Physician Consortium 2008 Clinical Performance Measures for Adults with Nonvalvular Atrial Fibrillation or Atrial Flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation) Developed in Collaboration with the Heart Rhythm Society. J Am Coll Cardiol. 2008 Feb 26; 51(8):865-84.
    View in: PubMed
    Score: 0.063
  101. ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation): developed in collaboration with the Heart Rhythm Society. Circulation. 2008 Feb 26; 117(8):1101-20.
    View in: PubMed
    Score: 0.063
  102. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med. 2007 Aug; 120(8):700-5.
    View in: PubMed
    Score: 0.060
  103. Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study. J Am Geriatr Soc. 2006 Aug; 54(8):1231-6.
    View in: PubMed
    Score: 0.056
  104. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004 Nov 16; 141(10):745-52.
    View in: PubMed
    Score: 0.050
  105. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):429S-456S.
    View in: PubMed
    Score: 0.049
  106. ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Commitee to Develop Data Standards on Atrial Fibrillation). J Am Coll Cardiol. 2004 Jul 21; 44(2):475-95.
    View in: PubMed
    Score: 0.049
  107. ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Data Standards on Atrial Fibrillation). Circulation. 2004 Jun 29; 109(25):3223-43.
    View in: PubMed
    Score: 0.049
  108. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003 Sep 11; 349(11):1019-26.
    View in: PubMed
    Score: 0.046
  109. Comparison of the ATRIA, CHADS2, and CHA2DS2-VASc stroke risk scores in predicting ischaemic stroke in a large Swedish cohort of patients with atrial fibrillation. Eur Heart J. 2016 Nov 07; 37(42):3203-3210.
    View in: PubMed
    Score: 0.027
  110. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011 Jul 19; 58(4):395-401.
    View in: PubMed
    Score: 0.020

© 2025 Kaiser Permanente

Your Privacy Choices